BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, the first TKI approved for clinical use, targets the BCR-ABL fusion protein in chronic myelogenous leukemia (CML), providing a revolutionary treatment option for CML patients with Philadelphia chromosome-positive tumors.